ZURA

Zura BioD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$9.00

+119.5% vs current

Most likely

Base case

45%

Probability

Target price

$5.00

+22.0% vs current

B-

Bear case

30%

Probability

Target price

$2.50

-39.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Primary-source support is solid, but forward visibility is still mostly a filing-and-readout monitoring story. The February 2026 financing removed the most immediate balance-sheet pressure, yet the deterministic score remains negative and the stock still needs Phase 2 execution to justify a durable re-rating. This looks more like a cautious clinical-event setup than a high-conviction fundamental long.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-15eventFebruary financing materially extends runwayHigh impact

Management said that, after the February 2026 public offering, existing cash, cash equivalents, and investments should fund operations through at least the end of 2028, reducing near-term financing pressure but not eliminating dilution risk in a pre-revenue biotech [#10-K-2026-03-19] [#8-K-2026-03-19].

2026-11-15catalystTibuSHIELD Phase 2 hidradenitis suppurativa topline in Q4 2026High impact

The 10-K and March 2026 corporate presentation say topline results from the 16-week double-blind portion of TibuSHIELD are expected in the fourth quarter of 2026; this is the nearest clear clinical value inflection for tibulizumab [#10-K-2026-03-19] [#8-K-2026-03-19].

2027-06-30catalystTibuSURE Phase 2 systemic sclerosis topline in 1H 2027High impact

Zura states topline results from the 24-week double-blind portion of TibuSURE are expected in the first half of 2027, creating a second and likely more binary readout after HS given the smaller program and orphan-disease framing [#10-K-2026-03-19] [#8-K-2026-03-19].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology